Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

LETROZOLE\RIBOCICLIB for Neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 16 adverse event reports in the FDA FAERS database where LETROZOLE\RIBOCICLIB was used for Neoplasm malignant.

Most Reported Side Effects for LETROZOLE\RIBOCICLIB

Side Effect Reports % Deaths Hosp.
Fatigue 69 11.1% 3 11
Death 66 10.6% 66 0
Nausea 57 9.2% 3 3
White blood cell count decreased 39 6.3% 2 6
Diarrhoea 35 5.6% 0 6
Rash 27 4.4% 1 0
Alopecia 25 4.0% 0 3
Neoplasm malignant 25 4.0% 1 3
Malaise 24 3.9% 0 1
Cough 22 3.5% 0 3
Disease progression 22 3.5% 1 1
Product dose omission issue 22 3.5% 0 5
Vomiting 22 3.5% 0 3
Headache 21 3.4% 0 2
Drug ineffective 20 3.2% 0 1

Other Indications for LETROZOLE\RIBOCICLIB

Product used for unknown indication (327) Breast cancer (114) Breast cancer female (47) Breast cancer metastatic (44)

Other Drugs Used for Neoplasm malignant

PALBOCICLIB (1,996) CAPECITABINE (1,493) PEMBROLIZUMAB (1,135) PACLITAXEL (984) CARBOPLATIN (977) NIVOLUMAB (947) OXALIPLATIN (823) PAZOPANIB (716) CYCLOPHOSPHAMIDE (685) FLUOROURACIL (676)

Related Pages

LETROZOLE\RIBOCICLIB Full Profile All Neoplasm malignant Drugs LETROZOLE\RIBOCICLIB Demographics LETROZOLE\RIBOCICLIB Timeline